TAK vs. SNY, GSK, MRNA, TEVA, BGNE, RDY, CTLT, QGEN, PCVX, and ROIV
Should you be buying Takeda Pharmaceutical stock or one of its competitors? The main competitors of Takeda Pharmaceutical include Sanofi (SNY), GSK (GSK), Moderna (MRNA), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Qiagen (QGEN), Vaxcyte (PCVX), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry.
Takeda Pharmaceutical (NYSE:TAK) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, community ranking, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.
In the previous week, Sanofi had 20 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 21 mentions for Sanofi and 1 mentions for Takeda Pharmaceutical. Sanofi's average media sentiment score of 0.62 beat Takeda Pharmaceutical's score of 0.47 indicating that Sanofi is being referred to more favorably in the news media.
Sanofi has a net margin of 10.52% compared to Takeda Pharmaceutical's net margin of 6.18%. Sanofi's return on equity of 26.25% beat Takeda Pharmaceutical's return on equity.
Sanofi has higher revenue and earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.
Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 3.5%. Sanofi pays an annual dividend of $1.47 per share and has a dividend yield of 2.8%. Takeda Pharmaceutical pays out 87.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi pays out 73.9% of its earnings in the form of a dividend.
Takeda Pharmaceutical presently has a consensus target price of $14.00, suggesting a potential upside of 1.67%. Sanofi has a consensus target price of $57.50, suggesting a potential upside of 9.73%. Given Sanofi's higher probable upside, analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical.
Takeda Pharmaceutical has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.
9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 10.0% of Sanofi shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Takeda Pharmaceutical received 65 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 56.82% of users gave Takeda Pharmaceutical an outperform vote while only 54.69% of users gave Sanofi an outperform vote.
Summary
Sanofi beats Takeda Pharmaceutical on 16 of the 19 factors compared between the two stocks.
Get Takeda Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Takeda Pharmaceutical Competitors List
Related Companies and Tools
